^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + AU-16770 (CDK12 inhibitor, CDK13 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance
Published date:
04/12/2023
Excerpt:
...we investigated the efficacy of two novel CDK12/13 inhibitors, AU-15506 and AU-16770, in osimertinib-resistant EGFR mutant lung adenocarcinoma cells in culture and xenograft models in vivo...only the CDK12/13 inhibitor in combination with osimertinib, although not as monotherapy, suppresses the growth of resistant tumors in xenograft models in vivo...AU-16770 was also found to be very effective in preventing xenograft tumor growth at 28 days when administered in combination with osimertinib (Figure 4A–E).
DOI:
https://doi.org/10.3390/cancers15082263
